Sequence Information

    • DRAMP ID

    • DRAMP18067

    • Name

    • Dalbavancin (BI397, Dalvance, Xydalba)

    • Sequence

    • Not available

    • Description

    • Dalbavancin is a semisynthetic lipoglycopeptide and derivate of teicoplanin. It is an antibacterial used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria.

    • Activity

    • Antibacterial

    • Target Organism

      • No MICs found on DRAMP database

    • Reference

      • Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.(PMID: 25578881)
      • Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review.(PMID: 18728718)

Clinical Information

    • Medical use

    • Acute bacterial skin infections, Osteomyelitis and septic arthritis(Phase IV)

    • Company

    • Allergan (formerly Actavis and Durata Therapeutics)

    • Stage of Development

    • In market

    • Comments

    • The bactericidal action of dalbavancin results primarily from inhibition of cell-wall biosynthesis. Specifically, dalbavancin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls.